OpGen, Inc.

  • Market Cap: Micro Cap
  • Industry: Miscellaneous
  • ISIN: US68373L4068
USD
10.00
1 (11.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About OpGen, Inc. stock-summary
stock-summary
OpGen, Inc.
Miscellaneous
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Company Coordinates stock-summary
Company Details
708 Quince Orchard Rd Ste 205 , GAITHERSBURG MD : 20878-1793
stock-summary
Tel: 1 240 81312601 240 8131273
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.3%)

Foreign Institutions

Held by 8 Foreign Institutions (0.21%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. William Rhodes
Chairman of the Board
Mr. Oliver Schacht
President, Chief Executive Officer, Director
Mr. Mario Crovetto
Director
Dr. Prabhavathi Fernandes
Director
Mr. Evan Jones
Director
Mr. R. Donald Elsey
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Dec 2024)
Net Profit:
4 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 0 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.14

stock-summary
Return on Equity

-5.37%

stock-summary
Price to Book

0.00